XML 59 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segments of business and geographic areas
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segments of business and geographic areas Segments of business and geographic areas
Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine (formerly referred to as Pharmaceutical) and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
INNOVATIVE MEDICINE(1)
Immunology
     U.S.$11,53911,03610,8434.6 %1.8 
     International6,5135,8995,90710.4 (0.1)
     Worldwide 18,05216,93516,7506.6 1.1 
     REMICADE
     U.S.1,1431,4172,019(19.3)(29.8)
     U.S. Exports147204236(28.0)(13.6)
     International549722935(23.9)(22.8)
     Worldwide 1,8392,3433,190(21.5)(26.6)
     SIMPONI / SIMPONI ARIA
     U.S.1,1241,1661,127(3.6)3.5 
     International1,0731,0171,1485.4 (11.4)
     Worldwide 2,1972,1842,2760.6 (4.0)
     STELARA
     U.S.6,9666,3885,9389.0 7.6 
     International3,8923,3353,19616.7 4.4 
     Worldwide 10,8589,7239,13411.7 6.5 
     TREMFYA
     U.S.2,1471,8441,50316.5 22.7 
     International99982462421.2 32.0 
     Worldwide 3,1472,6682,12717.9 25.4 
     OTHER IMMUNOLOGY
     U.S.111721(33.8)(18.4)
     International003— *
     Worldwide 111724(33.8)(28.2)
Infectious Diseases
     U.S.1,5001,6802,249(10.7)(25.3)
     International2,9183,7693,576(22.6)5.4 
     Worldwide 4,4185,4495,825(18.9)(6.5)
     COVID-19 VACCINE
U.S.0120634*(81.1)
International1,1172,0591,751(45.8)17.6 
Worldwide1,1172,1792,385(48.8)(8.6)
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
     EDURANT / rilpivirine
     U.S.353641(3.7)(10.8)
     International1,11597295314.8 2.0 
     Worldwide 1,1501,00899414.1 1.5 
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
     U.S.1,4461,4941,508(3.2)(1.0)
     International408449575(9.2)(21.9)
     Worldwide 1,8541,9432,083(4.6)(6.7)
     OTHER INFECTIOUS DISEASES
     U.S.193066(34.5)(55.5)
     International278289297(3.8)(2.6)
     Worldwide 297318363(6.7)(12.3)
Neuroscience
     U.S.4,0653,5703,34713.9 6.7 
     International3,0763,3233,641(7.5)(8.7)
     Worldwide 7,1406,8936,9883.6 (1.4)
     CONCERTA / methylphenidate
     U.S.23015117252.5 (12.5)
     International55449349512.2 (0.4)
     Worldwide 78364466721.6 (3.5)
       INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
     U.S.2,8972,7142,5506.7 6.5 
     International1,2181,4261,472(14.6)(3.1)
     Worldwide 4,1154,1404,022(0.6)3.0 
     SPRAVATO
     U.S.58932819879.7 65.7 
     International1004626*76.9 
     Worldwide 68937422484.1 67.0 
     OTHER NEUROSCIENCE(2)
     U.S.349376427(7.3)(11.9)
     International1,2041,3581,647(11.3)(17.5)
     Worldwide 1,5531,7342,074(10.4)(16.4)
Oncology
     U.S.8,4626,9305,95822.1 16.3 
     International9,1999,0528,5901.6 5.4 
     Worldwide 17,66115,98314,54810.5 9.9 
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
      CARVYKTI
     U.S.469133—**
     International30——**
     Worldwide500133—**
     DARZALEX
     U.S.5,2774,2103,16925.4 32.8 
     International4,4673,7672,85418.6 32.0 
     Worldwide 9,7447,9776,02322.2 32.4 
     ERLEADA
     U.S.1,06596881310.0 19.2 
     International1,32291347844.8 *
     Worldwide2,3871,8811,29126.9 45.7 
     IMBRUVICA
     U.S.1,0511,3901,747(24.4)(20.4)
     International2,2142,3942,622(7.5)(8.7)
     Worldwide 3,2643,7844,369(13.7)(13.4)
     ZYTIGA /abiraterone acetate
     U.S.5074119(32.1)(37.8)
     International8371,6962,178(50.7)(22.1)
     Worldwide 8871,7702,297(49.9)(22.9)
     OTHER ONCOLOGY
     U.S.549156110*41.8 
     International33028345816.9 (38.2)
     Worldwide 879438568*(22.9)
Pulmonary Hypertension
     U.S.2,6972,3462,36515.0 (0.8)
     International1,1171,0711,0854.3 (1.3)
     Worldwide 3,8153,4173,45011.6 (1.0)
     OPSUMIT
     U.S.1,2921,1321,14714.1 (1.3)
     International6816516724.6 (3.2)
     Worldwide 1,9731,7831,81910.6 (2.0)
     UPTRAVI
     U.S.1,3261,1041,05620.1 4.5 
     International25521818117.3 20.4 
     Worldwide 1,5821,3221,23719.7 6.9 
     OTHER PULMONARY HYPERTENSION
     U.S.79110163(28.6)(32.3)
     International182202232(10.3)(12.8)
     Worldwide 260313395(16.7)(20.8)
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
Cardiovascular / Metabolism / Other
     U.S.2,9063,0423,192(4.5)(4.7)
     International765845927(9.4)(8.9)
     Worldwide 3,6713,8874,119(5.5)(5.6)
     XARELTO
     U.S.2,3652,4732,438(4.4)1.4 
     International———— — 
     Worldwide 2,3652,4732,438(4.4)1.4 
     OTHER(3)
     U.S.541569754(5.0)(24.5)
     International765845927(9.4)(8.8)
     Worldwide 1,3061,4141,682(7.6)(15.9)
TOTAL INNOVATIVE MEDICINE
     U.S.31,16928,60427,9549.0 2.3 
     International23,59023,95923,726(1.5)1.0 
     Worldwide 54,75952,56351,6804.2 1.7 
MEDTECH
Interventional Solutions
     U.S.3,6332,1691,83667.5 18.2 
     International2,7172,1312,13527.5 (0.2)
     Worldwide 6,3504,3003,97147.7 8.3 
     ELECTROPHYSIOLOGY
     U.S.2,4582,0361,73020.7 17.7 
     International2,2301,9011,89317.3 0.4 
     Worldwide4,6883,9373,62319.1 8.7 
     ABIOMED(4)
     U.S.1,06631—**
     International240——**
     Worldwide1,30631—**
     OTHER INTERVENTIONAL SOLUTIONS
     U.S.1091021066.7 (3.8)
     International2472302427.3 (5.0)
     Worldwide3563323487.1 (4.6)
Orthopaedics
     U.S.5,5255,3215,1263.8 3.8 
     International3,4173,2673,4624.6 (5.6)
     Worldwide 8,9428,5878,5884.1 0.0 
     HIPS
     U.S.9969438785.6 7.3 
     International564571602(1.2)(5.1)
     Worldwide 1,5601,5141,4803.0 2.3 
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
     KNEES
     U.S.8968517875.3 8.2 
     International55950853810.2 (5.7)
     Worldwide 1,4561,3591,3257.1 2.6 
     TRAUMA
     U.S.1,9491,8821,8193.6 3.5 
     International1,0309891,0664.1 (7.2)
     Worldwide 2,9792,8712,8853.8 (0.5)
     SPINE, SPORTS & OTHER
     U.S.1,6841,6451,6422.4 0.2 
     International1,2631,1981,2565.4 (4.6)
     Worldwide 2,9472,8432,8983.7 (1.9)
Surgery
     U.S.4,0313,8973,8673.4 0.8 
     International6,0065,7935,9453.7 (2.6)
     Worldwide 10,0379,6909,8123.6 (1.2)
     ADVANCED
     U.S.1,8331,7841,7612.8 1.3 
     International2,8372,7852,8611.9 (2.6)
     Worldwide 4,6714,5694,6222.2 (1.1)
     GENERAL
     U.S.2,1982,1132,1054.0 0.4 
     International3,1683,0083,0855.3 (2.5)
     Worldwide 5,3665,1215,1904.8 (1.3)
Vision
     U.S.2,0861,9901,8574.8 7.2 
     International2,9862,8592,8314.5 1.0 
     Worldwide 5,0724,8494,6884.6 3.4 
     CONTACT LENSES / OTHER
     U.S.1,6261,5221,3986.8 8.9 
     International2,0762,0222,0432.7 (1.0)
     Worldwide 3,7023,5433,4404.5 3.0 
     SURGICAL
     U.S.460468459(1.8)2.0 
     International9108377888.6 6.2 
     Worldwide 1,3701,3061,2484.9 4.6 
TOTAL MEDTECH   
     U.S.15,27513,37712,68614.2 5.4 
     International15,12514,05014,3747.7 (2.3)
     Worldwide 30,40027,42727,06010.8 1.4 
 Sales to Customers % Change
(Dollars in Millions)202320222021’23 vs. ’22’22 vs. ’21
WORLDWIDE   
     U.S.46,44441,98140,64010.6 3.3 
     International38,71538,00938,1001.9 (0.2)
     Worldwide $85,15979,99078,7406.5 %1.6 
*Percentage greater than 100% or not meaningful
(1)Previously referred to as Pharmaceutical
(2)Inclusive of RISPERDAL CONSTA which was previously disclosed separately
(3) Inclusive of INVOKANA which was previously disclosed separately
(4) Acquired on December 22, 2022

 Income Before TaxIdentifiable Assets
(Dollars in Millions)
2023 (3)
2022 (4)
2021 (5)
20232022
Innovative Medicine$18,24615,64717,750$58,32458,436
MedTech4,6694,4474,20874,71070,956
Total22,91520,09421,958133,034129,392
Less: Expense not allocated to segments (1)
7,8537352,780
Discontinued operations—27,237
General corporate (2)
34,52430,749
Worldwide total$15,06219,35919,178$167,558187,378

Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)202320222021202320222021
Innovative Medicine$1,6531,3741,198$3,8473,6874,029
MedTech2,3722,1201,9332,9432,3022,286
Segments total4,0253,4943,1316,7905,9896,315
Discontinued operations162303314383641739
General corporate356212207313340336
Worldwide total$4,5434,0093,652$7,4866,9707,390
 Sales to Customers
Long-Lived Assets (6)
(Dollars in Millions)20232022202120232022
United States$46,44441,98140,640$54,83258,750
Europe20,41020,66420,59531,61629,878
Western Hemisphere excluding U.S. 4,5494,1083,9271,4911,289
Asia-Pacific, Africa13,75613,23713,5781,5001,520
Segments total85,15979,99078,74089,43991,437
Discontinued operations—27,237
General corporate1,1921,081
Other non long-lived assets76,92767,623
Worldwide total$85,15979,99078,740$167,558187,378
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2023, the Company utilized three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total consolidated revenues. In fiscal year 2022, the Company had three wholesalers distributing products for both segments that represented approximately 18.9%, 15.0% and 13.8% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 16.6%, 12.6%, and 12.6% of the total consolidated revenues.
(1)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. Fiscal 2023 includes an approximately $7 billion charge related to talc matters (See Note 19, Legal proceedings, for additional details) and $0.4 billion related to the unfavorable change in the fair value of the retained stake in Kenvue.
(2)General corporate includes cash, cash equivalents and marketable securities.
(3)Innovative Medicine includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion
•A restructuring related charge of $0.5 billion
•Unfavorable changes in the fair value of securities of $0.4 billion
•Favorable litigation related items of $0.1 billion
•Loss on divestiture $0.2 billion.
•An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
MedTech includes:
•Acquired in process research and development asset of $0.4 billion related to the Laminar acquisition in 2023
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
•Income from litigation settlements of $0.1 billion
(4)Innovative Medicine includes:
•One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion
•An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS
•Litigation expense of $0.1 billion
•Unfavorable changes in the fair value of securities of $0.7 billion
•A restructuring related charge of $0.1 billion
MedTech includes:
•Litigation expense of $0.6 billion primarily for pelvic mesh related costs
•A restructuring related charge of $0.3 billion
•Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed
•A Medical Device Regulation charge of $0.3 billion
(5)Innovative Medicine includes:
•Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia
•Divestiture gains of $0.6 billion
•Gains of $0.5 billion related to the change in the fair value of securities
•A restructuring related charge of $0.1 billion
MedTech includes:
•An in-process research and development expense of $0.9 billion related to Ottava
•A restructuring related charge of $0.3 billion
•A Medical Device Regulation charge of $0.2 billion
•Litigation expense of $0.1 billion
(6)Long-lived assets include property, plant and equipment, net for fiscal years 2023, and 2022 of $19,898 and $17,982, respectively, and intangible assets and goodwill, net for fiscal years 2023 and 2022 of $70,733 and $74,536, respectively.